Try our Advanced Search for more refined results
Life Sciences
-
December 19, 2025
Medical, School Groups Seek Order Halting $100K Visa Fee
A medical practice in rural North Carolina and other employers asked a federal judge Friday to block enforcement of the Trump administration's $100,000 fee on H-1B visas, arguing the "massive" fee hike will inflict irreparable harm on their communities.
-
December 19, 2025
BigLaw And Boutiques Both Shine In 2025's Top 10 Deals
A tight circle of elite law firms guided the way as megadeals roared back with force in 2025, while a small group of specialist and international firms also made their mark across global transactions spanning infrastructure, gaming, pharmaceuticals, artificial intelligence and energy.
-
December 19, 2025
Taxation With Representation: Baker Botts, Morgan Lewis
In this week's Taxation With Representation, Trump Media and Technology Group merges with fusion power company TAE Technologies, pharmaceutical company Cencora boosts its stake in cancer care company OneOncology, and Phoenix Financial partners with private equity giant Blackstone to plug billions into various credit strategies.
-
December 19, 2025
J&J, ChemImage Reach Deal After $77M AI Patent Judgment
Johnson & Johnson has entered an agreement to resolve a lawsuit that ChemImage Corp. had brought alleging the pharmaceutical giant unilaterally ended a deal to develop in-surgery artificial intelligence imaging techniques, after a New York federal judge determined J&J owed $76.6 million in the dispute.
-
December 19, 2025
AbCellera Gets $36M In Cell Research Patent Settlement
Canadian biotechnology firm AbCellera said it had reached a $36 million settlement with Bruker Corp. to resolve patent infringement claims related to a cell analysis system.
-
December 19, 2025
Trump Admin Appeals Harvard Win In $2B Fund Freeze Case
The Trump administration will ask the First Circuit to overturn a federal judge's ruling that prevented the government from withholding $2.2 billion in federal grants from Harvard University over concerns about antisemitism on campus.
-
December 19, 2025
Biomedical Co. Gets Approval For Ch. 11 Auction In January
Eye disease treatment developer Clearside Biomedical on Friday got permission from a Delaware bankruptcy judge for a January auction of its assets after saying it had resolved objections from shareholders and the U.S. Trustee's Office.
-
December 19, 2025
BioMarin Inks $4.8B Amicus Buy As Patent Litigation Resolved
BioMarin Pharmaceutical Inc. has agreed to acquire Amicus Therapeutics for $4.8 billion, in a deal bolstered by Amicus' settlement of patent litigation that secures U.S. exclusivity for its Galafold drug until 2037, the companies said Friday.
-
December 18, 2025
The Biggest Rulings From A Busy Year At The 1st Circ.
The nation's smallest federal appellate panel punched above its weight in 2025, grappling with numerous suits against the Trump administration, high-profile criminal appeals, a $34 million legal fee bid and a hotly contested kickback law.
-
December 18, 2025
ITC Clears Toy Gun Imports, Will Review Smart Rings, Vapes
The U.S. International Trade Commission has had a busy week in intellectual property, determining a series of toy gun imports don't infringe Spin Master patents licensed to Hasbro, instituting reviews requested by companies including Ouraring, AbbVie and Juul, and receiving several new complaints.
-
December 18, 2025
Eli Lilly Workers Say Justices Needn't Mull Collective Standard
Eli Lilly workers on Wednesday pressed the U.S. Supreme Court not to disturb a Seventh Circuit decision establishing a new, more flexible standard for certifying collective actions, arguing that there's no "urgent" need for the high court to weigh in on the dispute.
-
December 18, 2025
InnovAge Investors Get Final OK For $27M Deal, Atty Fees
A Colorado federal judge has granted final approval to a $27 million settlement between InnovAge Holding Corp., its underwriters and a class of stockholders accusing the senior healthcare company of making misleading statements in an initial public offering that later caused stock prices to tank after a government audit exposed the alleged falsehoods.
-
December 18, 2025
Top Trade Secrets Decisions Of 2025
The Ninth Circuit clarified the rules of engagement in trade secrets disputes with guidance on when confidential information must be precisely detailed during litigation, and jurors delivered a $200 million verdict against Walmart over product freshness technology. Here are Law360's picks for the biggest trade secrets decisions of 2025.
-
December 18, 2025
Top Product Liability Cases Of 2025
The Fourth Circuit's decision to unravel an early landmark ruling in litigation over the opioid crisis in a suit brought by West Virginia counties against drug distributors tops Law360's list of product liability cases of the past year, as well as a loss for Tesla in a newsworthy trial over the automaker's Autopilot feature. Here's what other cases garnered attorneys' attention in 2025.
-
December 18, 2025
UC Researchers Near Reinstating $7B In DOE Grants
A California federal judge said Thursday she's inclined to grant a preliminary injunction ordering the Trump administration to reinstate $7 billion in Department of Energy grants awarded to researchers, saying they were canceled with form letters similar to those she's previously found to violate the Administrative Procedure Act.
-
December 18, 2025
SF Must Reinstate Worker Fired For Violating COVID Vax Rule
A California federal judge ordered San Francisco to reinstate a 311 call center agent who was fired for violating a COVID-19 vaccination mandate after he sought an exemption based on his Muslim faith, ruling Thursday that the plaintiff has made a "prima facie case for religious discrimination."
-
December 18, 2025
AstraZeneca Can't Block Colo. Law Over Drug Discount Rules
A Colorado federal judge rejected AstraZeneca's effort to block enforcement of a Colorado law surrounding federal 340B drug pricing that requires manufacturers to sell drugs at discounted prices to certain safety net healthcare facilities, ruling Wednesday the law isn't preempted by 340B drug pricing.
-
December 18, 2025
HHS Proposes Hospital Ban On Gender Care For Minors
The Trump administration moved to block all hospitals that receive federal funding from providing gender-affirming care to minors and issued warning letters to a dozen companies Thursday as part of a sweeping push to halt the care nationwide, even in states with legal protections in place.
-
December 18, 2025
Agita Over Piglets At Party Got Pharma Exec Axed, Suit Says
The U.S. arm of a Danish pharmaceutical company pushed out a director after he expressed concerns about using baby pigs for a photo op at the company's anniversary party knowing the animals would be euthanized after, a new federal lawsuit alleges.
-
December 18, 2025
Trump Orders Loosening Of Federal Restrictions On Marijuana
President Donald Trump on Thursday announced that his administration would instruct federal agencies to loosen restrictions on cannabis via executive order, a historic acknowledgment from the executive branch that the drug has recognized medical uses.
-
December 17, 2025
Sterne Kessler Draws Scolding, But No Sanctions Midtrial
A Delaware federal judge said Wednesday she wasn't happy with the tone used by attorneys defending a radiopharmaceutical company from patent infringement claims and that she does not condone the attorneys' conduct in improperly contacting three inventors named in a patent at issue, but she declined to issue the severe sanction of kicking them off the case.
-
December 17, 2025
Shutdown Deal Bars Federal Firings Until Feb., Judge Says
A California federal judge said Wednesday she'll grant a preliminary injunction barring layoffs of federal workers from several agencies before Jan. 30, saying legislation that ended the government shutdown prohibits the layoffs, but she added she might pause her order while the government appeals.
-
December 17, 2025
Conn. Zantac Injury Bellwether Trials Set To Begin In 2028
Bellwether trials in lawsuits against drugmaker Boehringer Ingelheim Pharmaceuticals Inc. over the side effects of Zantac are set to begin in Connecticut state court in March 2028, according to a court order.
-
December 17, 2025
Great American Says Cryo Unit Co. Hid Facts In Getting Policy
Insurer Great American has gone to California federal court asserting that it doesn't owe coverage to a cryotherapy unit seller for an underlying lawsuit involving an alleged injury in a hyperbaric chamber at the company's subsidiary, arguing that the cryotherapy company never told the insurer it had a subsidiary.
-
December 17, 2025
Doctors Not Harmed By CDC's Vaccine Guidance, Feds Say
The federal government argued Wednesday that doctors lack standing to challenge the overhaul of a key federal vaccine committee that has since downgraded the COVID-19 shot, saying healthcare providers haven't been harmed by the policy shifts.
Expert Analysis
-
How To Prep For Potential Passage Of SAFER Banking Act
The Secure and Fair Enforcement Regulation, or SAFER, Banking Act, could fundamentally reshape how financial institutions interact with cannabis businesses, so operators that move now to get their house in order will be best positioned to capitalize if and when change comes, says Alex Leonowicz at Howard & Howard.
-
A Former PTAB Judge Weighs The End Of Remote Hearings
Former Patent Trial and Appeal Board Judge Amanda Wieker, now at McGuireWoods, examines the costs and benefits of the PTAB's impending in-person hearing requirement, and offers suggestions for making the most out of this new regime.
-
The Future Of Lab-Test Regs After FDA Rescinds Rule
The U.S. Food and Drug Administration recently rescinded its laboratory-developed tests rule in response to a Texas federal court decision this spring, reinforcing a separation of authority between the FDA and the Centers for Medicare & Medicaid Services, and calling into question the FDA's role in overseeing such tests without congressional action, say attorneys at Venable.
-
SDNY Ruling Reinforces Joint Steering Committee Obligations
The recent Southern District of New York decision in ChemImage v. Johnson & Johnson makes joint steering committees a valuable tool in strategic relationships, as provisions for such committees can now be wielded to demand attention to core issues, say Lisa Bernstein at the University of Chicago Law School, and Reginald Goeke and Brad Peterson at Mayer Brown.
-
What 2 Profs Noticed As Transactional Law Students Used AI
After a semester using generative artificial intelligence tools with students in an entrepreneurship law clinic, we came away with numerous observations about the opportunities and challenges such tools present to new transactional lawyers, say professors at Cornell Law School.
-
What Patent Claim 'Invalidity' Means In Different Forums
A recent Federal Circuit order allowing a patent suit to proceed despite similar claims being invalidated in an inter partes review underscores how fractured the patent litigation landscape has become, leading to critical nuances in how district courts, the U.S. International Trade Commission and Patent Trial and Appeal Board treat invalidity, says Jason Hoffman at BakerHostetler.
-
Rebuttal
BigLaw Settlements Should Not Spur Ethics Deregulation
A recent Law360 op-ed argued that loosening law firm funding restrictions would make BigLaw firms less inclined to settle with the Trump administration, but deregulating legal financing ethics may well prove to be not merely ineffective, but counterproductive, says Laurel Kilgour at the American Economic Liberties Project.
-
How Big Pharma Has Responded To FTC Delisting Demands
Looking at some statistics concerning how pharmaceutical companies have responded to the Federal Trade Commission's recent challenges to Orange Book listings raises several possible hypotheses about the FTC's strategy and effectiveness, say Ratib Ali and Celia Lu at Competition Dynamics.
-
5 Ways Lawyers Can Earn Back The Public's Trust
Amid salacious headlines about lawyers behaving badly and recent polls showing the public’s increasingly unfavorable view of attorneys, we must make meaningful changes to our culture to rebuild trust in the legal system, says Carl Taylor at Carl Taylor Law.
-
USPTO's AI Tool Redefines Design Patent Landscape
The U.S. Patent and Trademark Office's newly introduced DesignVision tool for artificial intelligence-powered image searching represents a dramatic shift in how design patent applications are examined, necessitating new strategies for patent practitioners, says Matthew Epstein at Dinsmore.
-
Class Actions At The Circuit Courts: August Lessons
In this month's review of class action appeals, Mitchell Engel at Shook Hardy discusses key takeaways from federal appellate decisions involving topics including antitrust, immigration, consumer fraud, birthright citizenship under the Fourteenth Amendment, and product defects.
-
Series
Hiking Makes Me A Better Lawyer
On the trail, I have thought often about the parallels between hiking and high-stakes patent litigation, and why strategizing, preparation, perseverance and joy are important skills for success in both endeavors, says Barbara Fiacco at Foley Hoag.
-
What US-India Trade Deal Will Mean For Indian Pharma
Complicated by newly imposed tariffs from the U.S., the outcome of the U.S.-India trade talks is poised to reshape not just trade policy, but also the strategic alignment of the two countries' pharmaceutical ecosystems, says Jashaswi Ghosh at Holon Law Partners.
-
Opinion
Time For Full Disclosure Of Third-Party Funding In MDLs
It is appropriate that the Federal Advisory Committee on Civil Rules is considering a rule to require disclosure of third-party litigation funding in civil litigation — something that is particularly needed in multidistrict litigation, which now comprises more than half of all civil cases in the federal courts, says Eric Hudson at Butler Snow.
-
Series
Law School's Missed Lessons: Negotiation Skills
I took one negotiation course in law school, but most of the techniques I rely on today I learned in practice, where I've discovered that the process is less about tricks or tactics, and more about clarity, preparation and communication, says Grant Schrantz at Haug Barron.